AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1917
- Registration Number
- NCT01242514
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Epanova® for Lowering Very High Triglycerides
Phase 2
Completed
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: placeboDrug: omefas
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 399
- Registration Number
- NCT01242527
China Survey of Peptic Ulcer Bleeding
Completed
- Conditions
- Peptic Ulcer Hemorrhage
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1044
- Registration Number
- NCT01241266
- Locations
- 🇨🇳
Research Site, Wenzhou, Zhejiang, China
To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function
Phase 1
Completed
- Conditions
- Healthy VolunteersPatientsPharmacokineticsRenal Impairment
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT01240967
- Locations
- 🇺🇸
Research site, Minneapolis, Minnesota, United States
🇺🇸Research Site, Orlando, Florida, United States
Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers
Phase 1
Completed
- Conditions
- Peripheral Neuropathic PainNociceptive Pain
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT01240148
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects
Phase 1
Completed
- Conditions
- Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT01239771
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes
Completed
- Conditions
- Acute Bipolar Manic Episode
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1280
- Registration Number
- NCT01239589
- Locations
- 🇬🇧
Research Site, Newcastle (Upon Tyne), United Kingdom
Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France
Withdrawn
- Conditions
- Self-administered Questionnaire to Patients
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7300
- Registration Number
- NCT01238809
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Phase 2
Terminated
- Conditions
- Obesity
- Interventions
- Drug: Pramlintide+MetreleptinDrug: Placebo
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 213
- Registration Number
- NCT01235741
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)Laymen Terminology Chronic Bronchitis and Emphysema
- Interventions
- Drug: AZD5069 50mgDrug: PlaceboDrug: AZD5069 80mg
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 109
- Registration Number
- NCT01233232
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine